FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients

Name: FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
Uploaded: 2023-12-18T21:12:02+00:00
Duration: 2 min 22 s
Description: Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

The Importance of Diversity in Clinical Trials
The Importance of Diversity in Clinical Trials
April 2025
The Importance of Diversity in Clinical Trials
Shahram Jacobs, MD
Shahram Jacobs, MD
Low-Nickel Diets Show Promise for Contact Dermatitis
Low-Nickel Diets Show Promise for Contact Dermatitis
Maui Derm Hawaii 2024
Low-Nickel Diets Show Promise for Contact Dermatitis
Matthew J. Zirwas, MD
Matthew J. Zirwas, MD
Seborrheic Dermatitis Update: A Review of the Etiology and Treatment of Seborrheic Dermatitis
Seborrheic Dermatitis Update: A Review of the Etiology and Treatment of Seborrheic Dermatitis
Other Dermatitis
Seborrheic Dermatitis Update: A Review of the Etiology and Treatment of Seborrheic Dermatitis
Peter Lio, MD; Christy Chang, BA
Peter Lio, MD; Christy Chang, BA
Diet and Inflammation in Dermatology
Diet and Inflammation in Dermatology
Other Dermatitis
Diet and Inflammation in Dermatology
Ronald Prussick, MD
Ronald Prussick, MD